FDG PET/CT in Breast Cancer Bone Mets

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Final enrollment: 26 participants (planned 75)
    • Interventions: FDG PET/CT scan (Other) to FDG PET/CT scan (Other)
    • Eligibility criteria expanded, about 12 words
  2. Study completion date: Jul 2025 to Jul 31, 2026v14
  3. Study completion date: Jul 2024 to Jul 2025v13
  4. Primary completion date changed from estimate of Jul 2023 to Jul 31, 2023
    • Study completion date: Jul 2023 to Jul 2024
    v12
  5. Primary and study completion dates: Jul 2022 to Jul 2023v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary and study completion dates: Jul 2021 to Jul 2022v10
  2. Primary and study completion dates: Jul 2020 to Jul 2021v9
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  4. Primary and study completion dates: Jul 2019 to Jul 2020v7
  5. Re-verified, no change to tracked fieldsv6
  6. Primary and study completion dates: Nov 2016 to Jul 2019v5
  7. Re-verified, no change to tracked fieldsv4
  8. Primary completion date: Nov 2015 to Nov 2016
    • Study completion date: Nov 2016
    v3
  9. Primary completion date: Jul 2015 to Nov 2015v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.
Trial Details
NCT Number NCT01996046
Lead Sponsor University of Pennsylvania
Conditions
(from sponsor)		 Estrogen Receptor Positive Breast Cancer, Bone Metastases
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov